Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncogene. 2014 Apr 10;33(15):1954-63. doi: 10.1038/onc.2013.143. Epub 2013 Apr 22.

The role of DAB2IP in androgen receptor activation during prostate cancer progression.

Author information

  • 11] Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA [2] Department of Urology, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • 2Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • 3Department of Bioengineering, University of Texas at Arlington, Arlington, TX, USA.
  • 4Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • 5Department of Urology, The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • 6Division of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • 7Vancouver Prostate Center, University of British Columbia, Vancouver, British Columbia, Canada.
  • 8Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • 9Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • 10Interdepartmental Program in Vascular Biology and Transplantation and Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
  • 11Department of Urology, China Medical University Hospital, Taichung, Taiwan.
  • 121] Graduate Institute of Cancer Biology, China Medical University Hospital, Taichung, Taiwan [2] Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan [3] Department of Biotechnology, Asia University, Taichung, Taiwan.
  • 131] Department of Urology, China Medical University Hospital, Taichung, Taiwan [2] School of Medicine, China Medical University, Taichung, Taiwan.
  • 14Department of General Surgery, Tongji Cancer Research Institute, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • 151] Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA [2] Graduate Institute of Cancer Biology, China Medical University Hospital, Taichung, Taiwan.

Abstract

Altered androgen-receptor (AR) expression and/or constitutively active AR are commonly associated with prostate cancer (PCa) progression. Targeting AR remains a focal point for designing new strategy of PCa therapy. Here, we have shown that DAB2IP, a novel tumor suppressor in PCa, can inhibit AR-mediated cell growth and gene activation in PCa cells via distinct mechanisms. DAB2IP inhibits the genomic pathway by preventing AR nuclear translocation or phosphorylation and suppresses the non-genomic pathway via its unique functional domain to inactivate c-Src. Also, DAB2IP is capable of suppressing AR activation in an androgen-independent manner. In addition, DAB2IP can inhibit several AR splice variants showing constitutive activity in PCa cells. In DAB2IP(-/-) mice, the prostate gland exhibits hyperplastic epithelia, in which AR becomes more active. Consistently, DAB2IP expression inversely correlates with AR activation status particularly in recurrent or metastatic PCa patients. Taken together, DAB2IP is a unique intrinsic AR modulator in normal cells, and likely can be further developed into a therapeutic agent for PCa.

PMID:
23604126
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk